Ocugen is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Co. develops, manufactures, and commercializes COVAXIN for the prevention of COVID-19. Co.'s gene therapy candidate, OCU400 is for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3, centrosomal protein 290, rhodopsin, and phosphodiesterase 6B mutation-associated inherited retinal degenerations. Co.'s second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A for the treatment of dry age-related macular degeneration. The OCGN average annual return since 2014 is shown above.
The Average Annual Return on the OCGN average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OCGN average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OCGN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|